Literature DB >> 29022408

Screening of colorectal cancer: present and future.

Marcello Maida1, Fabio Salvatore Macaluso2, Gianluca Ianiro3, Francesca Mangiola3, Emanuele Sinagra4, Georgina Hold5, Carlo Maida6, Giovanni Cammarota3, Antonio Gasbarrini3, Giuseppe Scarpulla1.   

Abstract

INTRODUCTION: Colorectal cancer (CRC) is the third most common cancer in males and second in females, and the fourth most common cause of cancer death worldwide. Currently, about 60-70% of diagnosed cases in symptomatic patients are detected at an advanced stage of disease. Earlier stage detection through the use of screening strategies would allow for better outcomes in terms of reducing the disease burden. Areas covered: The aim of this paper is to review the current published evidence from literature which assesses the performance and effectiveness of different screening tests for the early detection of CRC. Expert commentary: Adequate screening strategies can reduce CRC incidence and mortality. In the last few decades, several tests have been proposed for CRC screening. To date, there is still insufficient evidence to identify which approach is definitively superior, and no screening strategy for CRC can therefore be defined as universally ideal. The best strategy would be the one that can be economically viable and to which the patient can adhere best to over time. The latest guidelines suggest colonoscopy every 10 years or annual fecal immuno-chemical test (FIT) for people with normal risk, while for individuals with high risk or hereditary syndromes specific recommendations are provided.

Entities:  

Keywords:  Colorectal cancer; FIT; colonscopy; gFOBT; screening; surveillance

Mesh:

Year:  2017        PMID: 29022408     DOI: 10.1080/14737140.2017.1392243

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  40 in total

1.  Long non-coding RNA NKILA serves as a biomarker in the early diagnosis and prognosis of patients with colorectal cancer.

Authors:  Peng Jiang; Xiaoting Han; Yingnan Zheng; Jianchao Sui; Weiping Bi
Journal:  Oncol Lett       Date:  2019-06-24       Impact factor: 2.967

2.  Can we improve the efficiency of care in patients with colorectal cancer from the time of their initial referral for colonoscopy to surgical resection?

Authors:  Nicole Kloos; Daniela Keren; Sean Gregg; Anthony R. Maclean; Elijah Dixon; Rachid Mohamed; Ryan Rochon; Chad G. Ball
Journal:  Can J Surg       Date:  2019-02-01       Impact factor: 2.089

3.  Computational and Bioinformatics Methods for MicroRNA Gene Prediction.

Authors:  Ege Riza Karagur; Sakir Akgun; Hakan Akca
Journal:  Methods Mol Biol       Date:  2022

4.  Does Fellow Participation Increase the Adenoma Detection Rate?

Authors:  Emanuele Sinagra; Rita Alloro; Ilaria Tarantino
Journal:  Dig Dis Sci       Date:  2021-02-21       Impact factor: 3.199

5.  Comparison of multiple statistical models for the development of clinical prediction scores to detect advanced colorectal neoplasms in asymptomatic Thai patients.

Authors:  Kamonwan Soonklang; Boonying Siribumrungwong; Bunchorn Siripongpreeda; Chirayu Auewarakul
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

6.  MiR-130b-3p promotes colorectal cancer progression by targeting CHD9.

Authors:  Dan Song; Qian Zhang; Hao Zhang; Liangliang Zhan; Xinchen Sun
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

7.  A colorful approach towards developing new nano-based imaging contrast agents for improved cancer detection.

Authors:  Helen R Salinas; Dominie L Miyasato; Olga E Eremina; Rodolfo Perez; Karen L Gonzalez; Alexander T Czaja; Sean Burkitt; Arjun Aron; Augusta Fernando; Lauro S Ojeda; Kimberly N Larson; Ahmed W Mohamed; Jos L Campbell; Beth A Goins; Cristina Zavaleta
Journal:  Biomater Sci       Date:  2020-08-19       Impact factor: 6.843

8.  The impact of personalized clinical decision support on primary care patients' views of cancer prevention and screening: a cross-sectional survey.

Authors:  Daniel M Saman; Ella A Chrenka; Melissa L Harry; Clayton I Allen; Laura A Freitag; Stephen E Asche; Anjali R Truitt; Heidi L Ekstrom; Patrick J O'Connor; JoAnn M Sperl-Hillen; Jeanette Y Ziegenfuss; Thomas E Elliott
Journal:  BMC Health Serv Res       Date:  2021-06-21       Impact factor: 2.655

9.  Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells.

Authors:  Xin Xu; Jun Wang; Kunkun Han; Shaoyan Li; Feng Xu; Yili Yang
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

10.  Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.

Authors:  Hao Xie; Douglas W Mahoney; Patrick H Foote; Kelli N Burger; Karen A Doering; William R Taylor; Sara S Then; Xiaoming Cao; Maria McGlinch; Calise K Berger; Tsung-Teh Wu; Joleen M Hubbard; Hatim T Allawi; Michael W Kaiser; Graham P Lidgard; David A Ahlquist; John B Kisiel
Journal:  Clin Cancer Res       Date:  2020-10-07       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.